A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

. 2020 Oct 30 ; () : . [epub] 20201030

Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic

Typ dokumentu preprinty, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid33140046

Grantová podpora
N01AI30048 NIAID NIH HHS - United States
R24 AI120942 NIAID NIH HHS - United States

K777 is a di-peptide analog that contains an electrophilic vinyl-sulfone moiety and is a potent, covalent inactivator of cathepsins. Vero E6, HeLa/ACE2, Caco-2, A549/ACE2, and Calu-3, cells were exposed to SARS-CoV-2, and then treated with K777. K777 reduced viral infectivity with EC50 values of inhibition of viral infection of: 74 nM for Vero E6, <80 nM for A549/ACE2, and 4 nM for HeLa/ACE2 cells. In contrast, Calu-3 and Caco-2 cells had EC50 values in the low micromolar range. No toxicity of K777 was observed for any of the host cells at 10-100 μM inhibitor. K777 did not inhibit activity of the papain-like cysteine protease and 3CL cysteine protease, encoded by SARS-CoV-2 at concentrations of ≤ 100 μM. These results suggested that K777 exerts its potent anti-viral activity by inactivation of mammalian cysteine proteases which are essential to viral infectivity. Using a propargyl derivative of K777 as an activity-based probe, K777 selectively targeted cathepsin B and cathepsin L in Vero E6 cells. However only cathepsin L cleaved the SARS-CoV-2 spike protein and K777 blocked this proteolysis. The site of spike protein cleavage by cathepsin L was in the S1 domain of SARS-CoV-2 , differing from the cleavage site observed in the SARS CoV-1 spike protein. These data support the hypothesis that the antiviral activity of K777 is mediated through inhibition of the activity of host cathepsin L and subsequent loss of viral spike protein processing.

Aktualizováno

PubMed

Zobrazit více v PubMed

Zhou P, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273. PubMed PMC

Morse JS, Lalonde T, Xu S, & Liu WR (2020) Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem 21(5):730–738. PubMed PMC

Dong E, Du H, & Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases 20(5):533–534. PubMed PMC

New York Times (2020) Coronavirus in the U.S.: Latest Map and Case Count.

Pillaiyar T, Meenakshisundaram S, & Manickam M (2020) Recent discovery and development of inhibitors targeting coronaviruses. Drug Discovery Today 25(4):668–688. PubMed PMC

Guy RK, DiPaola RS, Romanelli F, & Dutch RE (2020) Rapid repurposing of drugs for COVID-19. Science 368(6493):829. PubMed

Rota PA, et al. (2003) Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. Science 300(5624):1394. PubMed

Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, & Fouchier RAM (2012) Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England Journal of Medicine 367(19):1814–1820. PubMed

Lu R, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565–574. PubMed PMC

Zhang L, et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368(6489):409. PubMed PMC

Báez-Santos YM, St John SE, & Mesecar AD (2015) The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral research 115:21–38. PubMed PMC

Li L, Li G, Chen J, Liang X, & Li Y (2020) Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13. bioRxiv:2020.2002.2027.969006. PubMed PMC

Heald-Sargent T & Gallagher T (2012) Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 4(4):557–580. PubMed PMC

Shang J, et al. (2020) Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences 117(21):11727. PubMed PMC

Ou X, et al. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications 11(1):1620. PubMed PMC

Belouzard S, Chu VC, & Whittaker GR (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences 106(14):5871. PubMed PMC

Millet JK & Whittaker GR (2014) Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National Academy of Sciences 111(42):15214. PubMed PMC

Hoffmann M, et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271–280.e278. PubMed PMC

Huang Y, Yang C, Xu X-f, Xu W, & Liu S-w (2020) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica 41(9):1141–1149 PubMed PMC

Simmons G, et al. (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proceedings of the National Academy of Sciences of the United States of America 102(33):11876. PubMed PMC

Zhou Y, et al. (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research 116:76–84. PubMed PMC

Bosch BJ, Bartelink W, & Rottier PJM (2008) Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide. Journal of Virology 82(17):8887. PubMed PMC

Riva L, et al. (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586(7827):113–119. PubMed PMC

Palmer JT, Rasnick D, Klaus JL, & Bromme D (1995) Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. Journal of Medicinal Chemistry 38(17):3193–3196. PubMed

Engel JC, Doyle PS, Hsieh I, & McKerrow JH (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 188(4):725–734. PubMed PMC

Yang PY, Wang M, He CY, Yao SQ. (2012) Proteomic profiling and potential cellular target identification of K11777, a clinical cysteine protease inhibitor, in Trypanosoma brucei. Chem Commun 48(6):835–837. PubMed

Doyle PS, Zhou YM, Engel JC, & McKerrow JH (2007) A Cysteine Protease Inhibitor Cures Chagas Disease in an Immunodeficient-Mouse Model of Infection. Antimicrobial Agents and Chemotherapy 51(11):3932. PubMed PMC

Barr SC, et al. (2005) A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrobial agents and chemotherapy 49(12):5160–5161. PubMed PMC

Abdulla M-H, Lim K-C, Sajid M, McKerrow JH, & Caffrey CR (2007) Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor. PLOS Medicine 4(1):e14. PubMed PMC

Ndao M, et al. (2013) A Cysteine Protease Inhibitor Rescues Mice from a Lethal Cryptosporidium parvum Infection. Antimicrobial Agents and Chemotherapy 57(12):6063. PubMed PMC

McKerrow JH (2018) Update on drug development targeting parasite cysteine proteases. PLoS neglected tropical diseases 12(8):e0005850–e0005850. PubMed PMC

Vuong W, et al. (2020) Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications 11(1):4282. PubMed PMC

Schneider CA, Rasband WS, & Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9(7):671–675. PubMed PMC

Thoms M, et al. (2020) Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 369(6508):1249. PubMed PMC

Cox J, et al. (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Molecular & cellular proteomics : MCP 13(9):2513–2526. PubMed PMC

Jaimes JA, André NM, Chappie JS, Millet JK, & Whittaker GR (2020) Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. Journal of molecular biology 432(10):3309–3325. PubMed PMC

Walls AC, et al. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2):281–292.e286. PubMed PMC

Tang T, et al. (2020) Proteolytic activation of the SARS-CoV-2 spike S1/S2 site: a re-evaluation of furin cleavage. bioRxiv:2020.2010.2004.325522.

Park J-E, et al. (2016) Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proceedings of the National Academy of Sciences 113(43):12262. PubMed PMC

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace